echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Digestive System Information > New VEGFR inhibitor Fruquintinib to treat metastatic colorectal cancer: Global Phase III trials have begun.

    New VEGFR inhibitor Fruquintinib to treat metastatic colorectal cancer: Global Phase III trials have begun.

    • Last Update: 2020-09-18
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Hutchison Whampoa has launched a Global Phase III Trial (FRESCO-2 Study) in the United States, Europe and Japan to assess the effectiveness and safety of Fruquintinib's treatment of metastatic colorectal cancer (CRC), the first of which was taken in the United States on September 3, 2020.
    FRESCO-2 is a randomized, double-blind, placebo-controlled multi-center trial for patients with metastasis CRC.
    the main endpoint of the study was the overall survival rate (OS).
    phase III trial will be conducted in approximately 130 locations in 10 countries.
    June 2020, the U.S. Food and Drug Administration (FDA) granted Fast Track eligibility for Fruquintinib therapeutic metastasis CRC.
    FRESCO-2 research design has also been reviewed and approved by the European Medicines Agency (EMA) and the Japan Pharmaceutical and Medical Devices Agency (PMDA).
    Fruquintinib is a highly selective oral inhibitor of vascular endostroin growth factor (VEGFR) 1/2/3.
    VEGFR inhibitors play a key role in blocking angiogenesics in tumors.
    Fruquintinib is designed to improve kinase selectivity to minimize off-target toxicity.
    to date, patients treated with Fruquintinib have generally had good tolerance, and according to preclinical assessment, Fruquintinib has no significant drug interaction, indicating that it is suitable for use in combination with other anticancer therapies.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.